PHILADELPHIA—End-stage renal disease patients who dialyzed with a portable hemodialysis (HD) system for 12 months reported improvements in their overall quality of life (QoL), according to findings presented at Kidney Week 2011.
Patients rated their QoL on a 10-point Likert scale (0 = worse, 10 = best). The QoL score rose significantly from 6.4 at baseline to 7.0 at the end of the study.
In addition, patients using the NxStage System One, a home use HD system approved by the FDA, are less likely to return to their previous dialysis regimen and are more satisfied with physical intimacy.
These findings were the latest in the ongoing Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements (FREEDOM) study, which uses self-reported data and is the largest study to measure the clinical and economic benefits of daily home HD treatments.
The NxStage System One requires no special infrastructure to operate and is just over a foot tall, allowing patients to travel with the machine. The product is manufactured by NxStage Medical, Inc. based in Lawrence, Mass.